Axsome Therapeutics Inc.

AI Score

0

Unlock

84.66
-4.61 (-5.16%)
At close: Jan 14, 2025, 3:59 PM
84.85
0.22%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 84.89
Market Cap 4.10B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -6.58
PE Ratio (ttm) -12.87
Forward PE n/a
Analyst Buy
Ask 86
Volume 562,933
Avg. Volume (20D) 627,234
Open 88.72
Previous Close 89.27
Day's Range 84.64 - 89.96
52-Week Range 64.11 - 105.00
Beta undefined

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2015
Employees 607
Stock Exchange NASDAQ
Ticker Symbol AXSM

Analyst Forecast

According to 14 analyst ratings, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is $121.5, which is an increase of 43.52% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Axsome Therapeutics Inc. is scheduled to release its earnings on Feb 18, 2025, before market opens.
Analysts project revenue of $117.89M, reflecting a 64.81% YoY growth and earnings per share of -1.03, making a 41.10% increase YoY.
1 day ago · Source
+11.52%
Axsome Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
2 months ago · Source
+9.35%
Axsome Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and provided updates regarding the cash on its balance sheet. Also, Needham reiterated a Buy rating on the stock.